Data Dictionary RNC - Luxembourg: Difference between revisions
No edit summary |
m (Update categories.) |
||
| Line 1: | Line 1: | ||
<span style="display:none">forresearchers</span> | |||
Go back to [[Database: National Register of Cancer (RNC) (Luxembourg)]] page | Go back to [[Database: National Register of Cancer (RNC) (Luxembourg)]] page | ||
Revision as of 13:27, 2 December 2025
Go back to Database: National Register of Cancer (RNC) (Luxembourg) page
Source: Click here to learn more
Information provided by hospital cancer registries (RHC)
Table 1: Patient identification.
| National pseudo-anonymization RNC number of the patient |
| Date of birth |
| Gender |
| Country of birth |
| Hospital file number |
| RHC registration number |
| Country of the patient |
| Postal code of the patient |
| Municipality of the patient |
| Referring primary care physician |
Table 2: Patient status.
| Vital status |
| Date of last contact |
| Date of death |
| Cause of death |
| Autopsy |
Table 3: Clinical description of the disease and staging.
| Order number of the tumour |
| RHC registration number of the tumour |
| Date of registration of the tumour |
| Date of tumour diagnosis |
| Basis of diagnosis |
| ICD code (topography and morphology) |
| Laterality |
| Multifocal tumour |
| Country of residence at the time of diagnosis |
| Postal code of residence at the time of diagnosis |
| Locality of residence at the time of diagnosis |
| Circumstances of tumour discovery |
| Family history |
| Personal history |
| Comorbidities |
| Performance score (WHO/ECOG) |
| Risk factors |
| Results of clinical examination (Initial assessment) |
| Types of performed tests (Initial assessment) |
| Tests dates (Initial assessment) |
| Tests results (Initial assessment) |
| Types of performed tests (staging evaluation) |
| Tests dates (staging evaluation) |
| Tests results (staging evaluation) |
| Tests date of serum tumour markers |
| Result of serum tumour markers |
| Laboratory of serum tumour markers |
| Clinical tumour size |
| Clinical lymph node involvement |
| Clinical TNM |
| Clinical metastases at the time of diagnosis |
Table 4: Histological characteristics of the tumour.
| Cytology procedure |
| Date of cytology procedure |
| Result of cytology procedure |
| Laboratory of cytology procedure |
| Biopsy procedure |
| Date of biopsy procedure |
| Result of biopsy procedure |
| Laboratory of biopsy procedure |
| Vascular invasion |
| Lymphatic invasion |
| Perineural sheath invasion |
| Vascular emboli |
| Capsular rupture |
| Percentage of tumour invasion |
| Distance from resection margins |
| Specific scores by location |
| Conducted analises of tissue tumour markers and molecular alterations |
| Date of analises of tissue tumour markers and molecular alterations |
| Result of analises of tissue tumour markers and molecular alterations |
| Laboratory of analises of tissue tumour markers and molecular alterations |
| Histological size |
| Pathological lymph node involvement |
| Number of examined and positive lymph nodes |
| Tumour residue |
| Pathological TNM, |
| Specific grade by location |
| Laboratory |
| Pathological Metastases at the time of diagnosis |
| Grouping by extension stages. |
Table 5: Revised diagnosis of the tumour.
| Revised incidence date |
| Revised basis of diagnosis |
| Revised ICD code (topography and morphology) |
| Laterality |
| Laboratory |
Table 6: Information on therapeutic management.
| Initial treatment performed |
| Inclusion in a therapeutic trial |
| Type of surgical intervention |
| Date of surgical intervention |
| Post-operative complications |
| Procedure for excision of regional lymph nodes |
| Surgeon's RNC identification number |
| Hospital facility |
| Date of discharge from hospital |
| Type of chemotherapy and drug molecules |
| Chemotherapy start date |
| Chemotherapy referring physician |
| Chemotherapy hospital facility. |
| Type of hormone therapy and drug molecules |
| Hormone terapy start date |
| Hormone terapy referring physician |
| Hormone therapy hospital facility |
| Type of radiotherapy |
| Radiotherapy irradiated fields |
| Radiotherapy start date |
| Radiotherapy total dose |
| Radiotherapy number of sessions |
| Radiotherapy referring physician |
| Radiotherapy center |
| Type of targeted therapy and drug molecules |
| Targeted Therapy start date |
| Targeted Therapy referring physician |
| Targeted Therapy hospital facility |
| Other Treatments |
| Date of genetic consultation |
| Location of genetic consultation. |
| Date of Multidisciplinary Consultation Meetings (RCP) |
| Location of RCP |
| Title of the RCP |
| RNC identification number of RCP attending physicians |
| Nature of RCP proposal |
| Proposed therapeutic protocol |
Table 7: Tumour follow-up.
| Location |
| Date of first recurrence |
| Basis of diagnosis |
| Location of first distant metastasis |
| Date of first distant metastasis |
Information provided by the National Breast Cancer Screening Program
Table 1: National RNC pseudo-anonymization number of the woman.
| Date of birth) |
| Country |
| Postal code |
| Locality (town/city) |
| Dates of Invitations to the Mammography Program |
| Dates of Participation in the Mammography Program |
| Dates of examinations conducted as part of the Mammography Program |
| Types of examinations conducted as part of the Mammography Program |
| Results of examinations conducted as part of the Mammography Program |
Information provided by the National Health Fund (CNS)
Table 1: Data to be transmitted to RNC per patient (Databases of patients treated abroad).
| National RNC Pseudo-anonymization Number of the patient |
| Date of birth |
| Gender |
| Country |
| Postal code |
| Locality (town/city) |
| Name and specialty of the physician who requested services abroad |
| Data on the pathology |
| Types of services |
| Dates of services |
| Locations of services |
Table 2: Data to be transmitted to RNC per hospital stay for cancer.
| National RNC Pseudo-anonymization Number of the patient |
| Date of birth |
| Gender |
| Country |
| Postal code |
| Locality (town/city) |
| ICD-10 Codes for the discharge diagnosis |
| Name of the hospital facility related to the considered hospital stay |
| Admission date |
| Discharge date |
| Mode of hospital discharge. |
Information provided by the Joint European Communities Health Insurance Scheme (RCAM)
Table 1: Data to be transmitted to RNC per patient.
| National RNC Pseudo-anonymization Number of the patient |
| Date of birth |
| Gender |
| Country |
| Postal code |
| Locality (town/city) |
| Name and specialty of the physician who requested services abroad |
| Data on the pathology |
| Types of services |
| Dates of services |
| Locations of services |
Table 2: Data to be transmitted to RNC per hospital stay for cancer.
| National RNC Pseudo-anonymization Number of the patient |
| Date of birth |
| Gender |
| Country |
| Postal code |
| Locality (town/city) |
| ICD-10 Codes for the discharge diagnosis |
| Name of the hospital facility related to the considered hospital stay |
| Admission date |
| Discharge date |
| Mode of hospital discharge |
Information provided by the Directorate of Health (death certificates)
Table 1: Data to be transmitted to RNC per deceased individual.
| National RNC Pseudo-anonymization Number of the patient |
| Date of birth |
| Gender |
| Country (at the time of death) |
| Postal code (at the time of death) |
| Locality (at the time of death) |
| Date of death |
| Place of death |
| Primary cause of death (1 ICD-10 code) |
| Immediate diseases (up to 3 possible ICD-10 codes) |
| Concurrent diseases (up to 2 possible ICD-10 codes). |
Information provided by the Civil status register
Table 1: Data to be transmitted to RNC per deceased individual.
| National RNC Pseudo-anonymization Number of the patient |
| Date of birth |
| Gender |
| Country (at the time of death) |
| Postal code (at the time of death) |
| Locality (at the time of death) |
| Date of death |
| Place of death |
Information provided by the private medical analysis laboratories
Table 1: Examinations reports sent by the laboratories to RNC.
| Analysis of Tumour Markers |
| Analysis of Serum Tumour Markers |
| Analysis of Tissue Tumour Markers |
| Analysis of Molecular Alterations with Predictive Value for Response to Chemotherapy or Targeted Therapy |
| Cytology performed in cases of severe dysplasia and malignant tumours |